Pharmaceuticals: Commission refines intellectual property rules

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU. The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Read more…